Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Bristol Myers Squibb (NYSE:BMY) Upgraded by Wall Street Zen to "Strong ...

AI-generated analysis

📈 Wall Street Zen upgraded Bristol Myers Squibb to a 'strong-buy' rating, adding to eight existing buy ratings from major analysts.

💰 The company reported Q1 EPS of $1.58, beating the consensus estimate of $1.42 by $0.16.

📊 Revenue reached $11.49 billion for the quarter, exceeding analyst estimates of $10.93 billion and growing 2.6% year-over-year.

🎯 Bristol Myers Squibb achieved a net margin of 15.01% and a return on equity of 64.87% during the reported period.

🔮 The company provided FY 2026 EPS guidance ranging from $6.05 to $6.35, aligning with analyst consensus of $6.32.

📉 EVP David V. Elkins sold 30,000 shares in April for a total transaction value of $1,850,100.

🏦 Hedge fund activity shows mixed signals, with NewEdge Advisors increasing its position by 12.9% while Basecamp Wealth Advisors lifted holdings by 13.8%.

📉 The current consensus analyst rating for the stock remains 'Hold' with a target price of $61.31.

💊 Bristol Myers Squibb focuses its portfolio on oncology, hematology, immunology, and cardiovascular disease through small molecules and biologics.

Bullish Signals
  • Bristol Myers Squibb beat quarterly earnings expectations with EPS of $1.58 versus the consensus estimate of $1.42.
  • Revenue of $11.49 billion exceeded analyst forecasts of $10.93 billion, demonstrating strong commercial performance.
  • The company delivered a robust net margin of 15.01% and a high return on equity of 64.87%.
  • Wall Street Zen upgraded the stock to 'strong-buy', signaling increased institutional confidence in the company's prospects.
  • FY 2026 guidance of $6.05-$6.35 EPS aligns well with analyst consensus, suggesting stable future expectations.
Risk Factors
  • Bank of America lowered its price target from $68.00 to $67.00, indicating some caution among analysts.
  • EVP David V. Elkins sold a significant portion of his holdings, reducing ownership by 15.85% in April.
Full Analysis
Wall Street Zen upgraded Bristol Myers Squibb (NYSE:BMY) to a 'strong-buy' rating, joining a mixed consensus of eight buy ratings, ten holds, and one sell. The stock currently trades with an average analyst target price of $61.31, reflecting varied sentiment among major institutions including recent downgrades from Bank of America and reaffirmations from Citigroup. The company reported strong quarterly financial results for the quarter ended April 30th, beating consensus estimates significantly. Bristol Myers Squibb generated revenue of $11.49 billion, surpassing analyst expectations of $10.93 billion, while posting earnings per share (EPS) of $1.58 against a consensus of $1.42. The firm achieved a net margin of 15.01% and a return on equity of 64.87%, with revenue growing 2.6% year-over-year. Looking ahead, Bristol Myers Squibb has set full-year 2026 EPS guidance between $6.05 and $6.35, which aligns closely with the average analyst prediction of $6.32 for the current fiscal year. Recent insider activity includes a notable sale by EVP David V. Elkins, who reduced his holdings by 15.85% in April, while several hedge funds have increased their stakes in the first quarter.